PubMed Health⌕ Search

Biomedical subjects

J Fabricius

Publications and source records attributed to J Fabricius.

At least 37 records · Page 2Linked to original sources
PubMed1985

Frequent attacks of supraventricular tachycardia in a patient treated with an automatic scanning pacemaker (PASAR): Holter documentation of 554 episodes.

A 68-year-old woman suffering from frequent attacks of supraventricular tachycardia received an implantable, automatic scanning pacemaker for tachycardia termination (PASAR). Electrophysiological study had shown the mechanism to be atrioventricular reentry with retrograde conduction through a concealed bypass tract. During 1 year of follow-up, a total of twenty-one 24-hour Holter recordings documented 554 episodes of tachycardia. In spite of marked fluctuation in tachycardia rate from 135 to 195 bpm and a considerable variation in diurnal pattern of onset of episodes, a clinical improvement resulted. Previous episodes of tachycardia had been isolated and of longer duration. Following implantation, an unexpected observation was made of numerous episodes of supraventricular tachycardia confined to periods lasting up to several hours. This pattern seemed to result from the efficacy of tachycardia termination combined with a continued presence of factors responsible for initiation of tachycardia.

Aged↗
PubMed1984

Sympathetic hyperreactivity in offspring of essential hypertensive patients.

A multistage exercise test was carried out in normotensive subjects with normotensive parents (controls; n = 12), and 32 offspring of essential hypertensive patients that were normotensive (NTO; n = 20) or borderline hypertensive (BHO; n = 12) The groups were comparable as to age, weight and working capacity. Changes in sympathetic nervous activity were determined by measurements of plasma noradrenaline. The initial rise in noradrenaline levels during the exercise test was proportional to the increase in work load until the noradrenaline concentration rose sharply to levels more than 1000 pg/ml above baseline levels. The work load immediately prior to the steep rise in plasma noradrenaline (sympathetic threshold level: STL) is considered to represent the point from which anaerobic energy-yielding processes play an increasingly greater role as the work load increases. The initial increase in plasma noradrenaline until STL was significantly higher in both the NTO (p less than 0.02) and BHO (p less than 0.005) compared to the control group. The absolute noradrenaline level at STL and the increase in noradrenaline from baseline to STL were significantly higher in the BHO group (p less than 0.02, p less than 0.005). No significant differences between the groups were found when comparing noradrenaline levels at rest or at absolute or relative work loads. The systolic blood pressure response during the exercise test was significantly more pronounced in the BHO group (p less than 0.05) compared to the controls and the NTO group.

Adolescent↗
PubMed1984

Dose-response relationship in normal subjects of prenalterol, a beta-adrenergic agonist with positive inotropic and resistance lowering effects.

The acute haemodynamic effects of increasing doses of parenterally administered prenalterol-a beta-adrenergic stimulating drug-were assessed in normal subjects by means of radionuclide ventriculography. Prenalterol induced dose-related increases in the left ventricular ejection fraction and the systolic pressure end-systolic volume ratio. Left ventricular end-systolic and end-diastolic volumes decreased to the same extent accounting for an unchanged stroke volume. Cardiac output increased due to a rise in the heart rate. Systolic blood pressure increased, whereas diastolic and mean blood pressure remained unchanged. Calculated total peripheral resistance decreased significantly. The maximum effect of prenalterol on cardiac performance occurred with a dose of 18 to 36 micrograms/kg. Plasma concentrations of prenalterol showed large interindividual variations. In conclusion, prenalterol improves the pump function of the normal heart and causes a fall in peripheral vascular resistance, implying a reduction of the load on the heart. These effects may prove beneficial in the treatment of acute heart failure.

Adrenergic beta-Agonists↗
PubMed1982

A controlled double-blind study of femoxetine and amitriptyline in patients with endogenous depression.

The new selective serotonin (5-HT)-uptake inhibitor femoxetine was compared with amitriptyline in a double-blind clinical trial comprising 77 depressed patients. The depressive symptoms were evaluated with the Hamilton rating scale, and a global clinical evaluation. Both drugs showed an antidepressive effect and no significant differences were found. Femoxetine induced a significantly lower frequency of dry mouth and blurred vision; this difference is presumably due to the weak anticholinergic effect of this substance. A small but significant weight loss was observed in the femoxetine group but not in the amitriptyline group.

Amitriptyline↗
PubMed1980

The spontaneous variation in the pattern of ventricular extrasystoles in patients recently recovered from an acute myocardial infarction.

Twelve patients between the ages of 40 and 68 years with myocardial infarction 1-6 months earlier were subjected to 24 h of ambulatory ECG monitoring for 2 consecutive d. In six patients with an average of less than 5 ventricular extrasystoles (VE) per hour during the first day, the pattern of the arrhythmias was both quantitatively and qualitatively unchanged from day to day. In six patients with an average of greater than 60 VE/h the first day, the number of VE were reduced significantly from the first to second day--in four patients by greater than 50%. The variation was greater after a day-to-day comparison than within the individual days following the division of the 24 h into 6-h periods. In general, the ventricular arrhythmias varied less following a qualitative rather than a quantitative evaluation. The evaluation of the effect of an antiarrhythmic drug in postmyocardial infarction patients requires that a considerable spontaneous variation should be taken into account when the patient is to be used as his own control. If a duration of monitoring of 24 h is employed both prior to and after the commencement of treatment, then the ventricular arrhythmias must practically disappear before the antiarrhythmic effect may be said to be documented.

Adult↗
PubMed1979

Paroxetine: pharmacokinetics, tolerance and depletion of blood 5-HT in man.

The tolerance of paroxetine (FG 7051), as well as its pharmacokinetics and reduction of 5-HT in blood, has been investigated in man. Three normal, healthy volunteers were administered the single doses 10, 25, 50, and 75 mg orally, and three volunteers received 10, 25, and 50 mg per day for seven or fourteen days. No toxic effect on blood, kidney, liver, heart or general condition was found by chemical and physical examinations. The pharmacokinetic studies revealed a dose dependent systemic availability, a rather slow elimination (t1-z2 = approximately 16 hrs), a good fit to one compartment open model, and an almost complete metabolism of the substance. 25 mg paroxetine per day gave a maximal reduction of 5-HT in the blood within 2--3 weeks (to approximately 0.03 microgram/ml). The 5-HT levels returned to the basic levels during a three to four weeks drug-free period.

Administration, Oral↗